Better Cancer Care

CuResponse is a clinical-stage cancer diagnostics company that is developing a 3-dimensional tissue culture system for modeling cancer growth and drug response. The platform preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine drug response for a specific individual's tumor type. Patients and clinicians would be able to send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment.

Leadership:

Investing partner / fund: